Skip to content

4896.T

K Pharma,Inc.

グロース · 医薬品 · 医薬品 · JP

JPY 699.00
−0.85%
Ask drillr

Year over year

Reported trailing growth

Revenue
—
EBITDA
—
EBIT
-9.6%
EPS
-17.4%
Free cash flow
—
Operating cash flow
—

Forward estimates

Based on analyst estimates

Revenue
—
EBITDA
—
EPS
-14.5%

Three-year CAGR

Revenue
—
EBITDA
—
EBIT
-9.6%
Net income
-17.4%
EPS
-17.3%
Free cash flow
+6.8%

Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026